Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Increasing cyclooxygenase-2 (cox-2) gene expression in the progression of Barrett's esophagus to adenocarcinoma correlates with that of Bcl-2.

Shimizu D, Vallböhmer D, Kuramochi H, Uchida K, Schneider S, Chandrasoma PT, Shimada H, DeMeester TR, Danenberg KD, Peters JH, DeMeester SR, Danenberg PV.

Int J Cancer. 2006 Aug 15;119(4):765-70.

2.

Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.

Ferguson HR, Wild CP, Anderson LA, Murphy SJ, Johnston BT, Murray LJ, Watson RG, McGuigan J, Reynolds JV, Hardie LJ.

Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):727-31. doi: 10.1158/1055-9965.EPI-07-2570.

3.
4.

Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis.

Ishimura N, Amano Y, Sanchez-Siles AA, Fukuhara H, Takahashi Y, Uno G, Tamagawa Y, Mishima Y, Yuki T, Ishihara S, Kinoshita Y.

J Clin Gastroenterol. 2011 Sep;45(8):665-72. doi: 10.1097/MCG.0b013e318207f240.

PMID:
21325951
5.

Coamplification and coexpression of GRB7 and ERBB2 is found in high grade intraepithelial neoplasia and in invasive Barrett's carcinoma.

Walch A, Specht K, Braselmann H, Stein H, Siewert JR, Hopt U, Höfler H, Werner M.

Int J Cancer. 2004 Dec 10;112(5):747-53.

6.

Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.

Abdalla SI, Lao-Sirieix P, Novelli MR, Lovat LB, Sanderson IR, Fitzgerald RC.

Clin Cancer Res. 2004 Jul 15;10(14):4784-92.

7.

Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects.

Majka J, Rembiasz K, Migaczewski M, Budzynski A, Ptak-Belowska A, Pabianczyk R, Urbanczyk K, Zub-Pokrowiecka A, Matlok M, Brzozowski T.

J Physiol Pharmacol. 2010 Aug;61(4):409-18.

8.

Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus.

Soslow RA, Remotti H, Baergen RN, Altorki NK.

Mod Pathol. 1999 Mar;12(3):239-50.

PMID:
10102608
9.

Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma.

Helm J, Enkemann SA, Coppola D, Barthel JS, Kelley ST, Yeatman TJ.

Clin Cancer Res. 2005 Apr 1;11(7):2478-85.

10.

Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.

Zou H, Molina JR, Harrington JJ, Osborn NK, Klatt KK, Romero Y, Burgart LJ, Ahlquist DA.

Int J Cancer. 2005 Sep 10;116(4):584-91.

11.

Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.

Kimchi ET, Posner MC, Park JO, Darga TE, Kocherginsky M, Karrison T, Hart J, Smith KD, Mezhir JJ, Weichselbaum RR, Khodarev NN.

Cancer Res. 2005 Apr 15;65(8):3146-54.

12.

Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma.

Kuramochi H, Vallböhmer D, Uchida K, Schneider S, Hamoui N, Shimizu D, Chandrasoma PT, DeMeester TR, Danenberg KD, Danenberg PV, Peters JH.

J Gastrointest Surg. 2004 Dec;8(8):1007-16; discussion 1016-7.

PMID:
15585388
14.
15.

Glutathione S-transferase-pi expression is downregulated in patients with Barrett's esophagus and esophageal adenocarcinoma.

Brabender J, Lord RV, Wickramasinghe K, Metzger R, Schneider PM, Park JM, Hölscher AH, DeMeester TR, Danenberg KD, Danenberg PV.

J Gastrointest Surg. 2002 May-Jun;6(3):359-67.

PMID:
12022988
16.

Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett's oesophagus and intestinal-type gastric carcinoma.

Sonoda R, Naomoto Y, Shirakawa Y, Fujiwara Y, Yamatsuji T, Noma K, Tanabe S, Takaoka M, Gunduz M, Tsujigiwa H, Nagatsuka H, Ohara N, Yoshino T, Takubo K, Vieth M, Tanaka N.

Histopathology. 2010 Jul;57(1):90-100. doi: 10.1111/j.1365-2559.2010.03594.x.

PMID:
20653782
17.

Association of COX-2 expression with corresponding active and chronic inflammatory reactions in Barrett's metaplasia and progression to cancer.

Ling FC, Baldus SE, Khochfar J, Xi H, Neiss S, Brabender J, Metzger R, Drebber U, Dienes HP, Bollschweiler E, Hoelscher AH, Schneider PM.

Histopathology. 2007 Jan;50(2):203-9. Erratum in: Histopathology. 2007 Mar;50(4):531.

PMID:
17222248
18.

A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus.

Brabender J, Marjoram P, Salonga D, Metzger R, Schneider PM, Park JM, Schneider S, Hölscher AH, Yin J, Meltzer SJ, Danenberg KD, Danenberg PV, Lord RV.

Oncogene. 2004 Jun 10;23(27):4780-8.

PMID:
15107828
19.
20.

Toll-like receptor 4 activation in Barrett's esophagus results in a strong increase in COX-2 expression.

Verbeek RE, Siersema PD, Ten Kate FJ, Fluiter K, Souza RF, Vleggaar FP, Bus P, van Baal JW.

J Gastroenterol. 2014 Jul;49(7):1121-34. doi: 10.1007/s00535-013-0862-6. Epub 2013 Aug 17.

PMID:
23955118

Supplemental Content

Support Center